Edition:
India

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

3.38USD
2:29am IST
Change (% chg)

$0.12 (+3.68%)
Prev Close
$3.26
Open
$3.22
Day's High
$3.38
Day's Low
$3.22
Volume
2,979
Avg. Vol
31,412
52-wk High
$28.23
52-wk Low
$1.88

Latest Key Developments (Source: Significant Developments)

Acer Therapeutics Reorganizes; Headcount Reduced To 19 Employees
Friday, 5 Jul 2019 

July 5 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS INC - HEADCOUNT HAS BEEN REDUCED FROM 48 TO 19 EMPLOYEES.ACER THERAPEUTICS INC - RESTRUCTURING EXPECTED TO EXTEND CASH RUNWAY THROUGH END OF 2020.ACER THERAPEUTICS INC - ACER PLANS TO DISCUSS EDSIVO CRL WITH FDA AND WILL CONTINUE TO ADVANCE ADDITIONAL PIPELINE PRODUCTS.ACER THERAPEUTICS INC - EXPECTS TO INITIATE A PIVOTAL BRIDGING STUDY IN Q4 2019 OF ACER-001 FOR UREA CYCLE DISORDERS (UCDS).ACER THERAPEUTICS - EXPECTS TO DISCLOSE SPECIFIC INDICATIONS FOR DEVELOPMENT OF OSANETANT IN LATE JULY 2019.ACER THERAPEUTICS INC - PRE-COMMERCIAL ACTIVITIES OF EDSIVO (CELIPROLOL) HAVE BEEN HALTED..ACER THERAPEUTICS INC - TO INITIATE A CLINICAL STUDY BY MID-2020 TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF OSANETANT .  Full Article

Acer Therapeutics Reports Fourth Quarter Loss Per Share Of $0.85
Friday, 8 Mar 2019 

March 7 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.85.Q4 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS WERE $41.7 MILLION AS OF DEC 31, 2018, COMPARED TO $15.6 MILLION AS OF DEC 31, 2017.  Full Article

Acer Therapeutics Announces In-License Of Osanetant From Sanofi
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES IN-LICENSE OF OSANETANT FROM SANOFI.ACER THERAPEUTICS INC - HAS ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH SANOFI TO ACQUIRE WORLDWIDE RIGHTS TO OSANETANT.ACER THERAPEUTICS INC - PLANS TO INITIALLY PURSUE DEVELOPMENT OF OSANETANT AS A POTENTIAL TREATMENT FOR CERTAIN NEUROENDOCRINE-RELATED DISORDERS.ACER THERAPEUTICS INC - FINANCIAL TERMS OF LICENSE AGREEMENT WERE NOT DISCLOSED.  Full Article

Acer Therapeutics Q3 Loss Per Share $0.43
Saturday, 10 Nov 2018 

Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.43.Q3 EARNINGS PER SHARE VIEW $-0.53 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS WERE $46.2 MILLION AS OF SEPTEMBER 30, 2018, COMPARED TO $15.6 MILLION AS OF DECEMBER 31, 2017.ACER THERAPEUTICS - BELIEVE CASH POSITION WILL BE SUFFICIENT TO FUND CURRENT OPERATING, CAPITAL REQUIREMENTS INTO H1 2020.  Full Article

Acer Therapeutics Says Entered License Agreement For Development And Exploitation With Assistance Publique - Hôpitaux De Paris
Wednesday, 26 Sep 2018 

Sept 25 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS - ON SEPT 19, ENTERED LICENSE AGREEMENT FOR DEVELOPMENT AND EXPLOITATION WITH ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS.ACER THERAPEUTICS-AGREEMENT TO ACQUIRE EXCLUSIVE WORLDWIDE INTELLECTUAL PROPERTY RIGHTS TO 3 PATENT APPLICATIONS RELATING TO CERTAIN USES OF CELIPROLOL.ACER THERAPEUTICS SAYS PURSUANT TO AGREEMENT, CO WILL REIMBURSE AP-HP FOR CERTAIN COSTS AND WILL PAY ANNUAL MAINTENANCE FEE PAYMENTS - SEC FILING.ACER THERAPEUTICS-UNDER AGREEMENT, CO WILL CONTROL AND PAY COSTS OF ONGOING PATENT PROSECUTION AND MAINTENANCE FOR LICENSED APPLICATIONS.  Full Article

Acer Therapeutics Announces Closing Of Underwritten Public Offering Of Common Stock
Friday, 15 Dec 2017 

Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.  Full Article

Acer Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - ANNOUNCED PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 916,667 SHARES OF COMMON STOCK AT $12.00/SHARE.  Full Article

Acer Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND RESEARCH AND DEVELOPMENT EFFORTS, TO SEEK REGULATORY APPROVAL FOR EDSIVO.ACER THERAPEUTICS INC - ALSO INTENDS TO USE NET PROCEEDS FROM OFFERING TO INVEST IN PRE-COMMERCIAL ACTIVITIES FOR EDSIVO, AMONG OTHERS.  Full Article

FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%.